From K-Beauty Icon to Global Favorite: A Cleansing Balm That Sets New Global Standards
Banila Co has been named the No. 1 global cleansing balm brand, according to the research by Euromonitor International.
- Banila Co ranked as the world's top-selling cleansing balm brand based on 2023 global retail sales
- Clean It Zero Cleansing Balm surpasses 90 million units sold worldwide
- Banila Co continues to expand its cleansing balm portfolio and launches special-edition collaborations
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- Makeup brand Banila Co announced that it has been named the world's top-selling cleansing balm brand[1], based on retail sales data compiled, according to data analytics company Euromonitor International.
Widely recognized as the cleansing balm, Banila Co has solidified its position as a leading K-beauty brand through proprietary beauty expertise and innovative technology. According to Euromonitor, the global cleansing balm market was valued at approximately USD 1.04 billion in 2023. Banila Co accounted for 22% share of global retail value sales, reinforcing its standing as the No. 1 brand worldwide[2] in this category.
At the heart of this success is Banila Co's flagship product, Clean It Zero Cleansing Balm, which has now sold more than 90 million units worldwide. Since its debut, Banila Co has consistently invested in research and development to enhance the product's efficacy, with these efforts playing a significant role in strengthening the brand's market position.
Clean It Zero Cleansing Balm is recognized for its ability to effectively remove makeup without leaving behind residue, while preserving key ingredients that nourish the skin. Its distinctive oil-balm formula melts seamlessly into the skin, delivering a gentle yet thorough deep-cleansing experience without causing irritation.
Banila Co has also expanded its product line to address a range of skin concerns. In addition to the existing Original, Pore Clarifying, Nourishing, and Calming variants, the brand recently introduced the Enriching Butter line, offering targeted cleansing solutions tailored to different skin types.
Furthermore, Banila Co has collaborated with popular characters such as Hello Kitty and My Melody to launch special-edition collections, transforming everyday cleansing into a joyful beauty ritual. Most recently, a playful partnership with The Powerpuff Girls has further strengthened Banila Co's distinctive brand identity and signature appeal.
A Banila Co spokesperson said, "We are honored that the excellence of our long-standing bestseller, Clean It Zero Cleansing Balm, has been recognized worldwide. We will continue to strive to earn even greater trust in the global beauty market by delivering exceptional beauty products."
[1] Source: Euromonitor International; Based on 2023 RSP Value Sales terms, Cleansing Balm sold via all retail channels (Research period: November 2024 ~ February 2025) |
[2] Source Euromonitor International Limited; Based on Cleansing Balm product sold via retail in RSP value terms, 2023; Research conducted in November 2024 – February 2025. |
[1] Source: Euromonitor International; Based on 2023 RSP Value Sales terms, Cleansing Balm sold via all retail channels (Research period: November 2024 ~ February 2025)
[2] Source Euromonitor International Limited; Based on Cleansing Balm product sold via retail in RSP value terms, 2023; Research conducted in November 2024 – February 2025.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BANILA CO Dominates the Global Cleansing Balm Market, Ranked No.1 Top Selling Cleansing Balm, by Euromonitor
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
